Regeneron Pharmaceuticals, Inc.
Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors

Abstract:

The present disclosure provides methods of treating patients having decreased bone mineral density, methods of identifying subjects having increased risk of developing decreased bone mineral density, methods of detecting human Zinc And Ring Finger 3 (ZNRF3) variant nucleic acid molecules and variant polypeptides, and ZNRF3 variant nucleic acid molecules and variant polypeptides.